A study published in the Journal Circulation deems better outcomes for patients affected from acute iliofemoral related deep venous thrombosis (DVT) treated with pharmacomechanical catheter-directed thrombolysis (PCDT). The authors of the study unveil that in patients affected from acute iliofemoral DVT, occurrence of recurrent venous thromboembolism (VTE) or post-thrombotic syndrome (PTS) is not influenced by PCDT.
PCDT has been deemed to provide immense reduction in the acute leg pain as well as swelling in patients having acute iliofemoral DVT. PCDT has also been observed to reduce PTS severity, and offer reduced severe-or-moderate PTS, along with greater improvement in the venous disease-specific life quality through 24 months.
Such catheter-based therapies continue to gain increased palpability across the globe in several surgical procedures, and Foley catheter is one such imperative variant that has gained immense prevalence as an effective urinary catheter. While catheterization is generally employed in treatment of most bladder dysfunction cases, Foley catheter has gained widespread acceptance in these surgeries worldwide.
According to the study, PCDT has resulted in lower PTS severity, in the ATTRACT trial evaluation of a group of 391 patients having acute iliofemoral DVT. From baseline, PCDT has also led to immense reduction in leg swelling and pain, and has offered better outcomes in the quality of life in cases of patients with venous disease.
Millar Wins CE Mark for its Mikro-Cath Pressure Catheter
Millar has recently been bestowed with a CE Mark approval extension for the company’s Mikro-Cath Pressure Catheter. The extension includes intra-compartmental and airway pressure measurements. The extension is expected to offer physicians with the opportunity of making improvements in the respiratory care, meanwhile delivering a constant monitoring technique to diagnose acute compartment syndrome and measure compartment pressure at onset.
Mikro-Cath Pressure Catheter enables easy integration into a more critical care program for trauma patients who require ventilation treatment. The Mikro-Cath Pressure Catheter provides an enhanced level of constant data accuracy for the compartment pressure and respiratory applications. Millar’s director of the international sales and business development states that the CE Mark extension for their Mikro-Cath Pressure Catheter has been a long-awaited approval.
The company looks forward to working with the physicians who have been interested in utilizing the Mikro-Cath Pressure Catheter for such applications. Millar further anticipates that the CE Mark extension approval will open doors to an improvement in the patient care, particularly in the respiratory market. Millar has also received the ISO 13485:2016 certificate for the company’s quality management system.